Neuropace Net Income Over Time
| NPCE Stock | USD 15.67 0.18 1.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neuropace Performance and Neuropace Correlation. Neuropace | Build AI portfolio with Neuropace Stock |
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Select Fundamental
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CERS | (14.7 M) | (17 M) | (15.9 M) | (43.3 M) | (38.6 M) | (55.9 M) | (62.9 M) | (60.6 M) | (57.6 M) | (71.2 M) | (59.9 M) | (54.4 M) | (42.8 M) | (37.5 M) | (20.9 M) | (18.8 M) | (19.8 M) |
| RXST | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 126.2 M | 27.6 M | (48.7 M) | (66.8 M) | (48.6 M) | (27.5 M) | (24.7 M) | (23.5 M) |
| CVRX | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.1 M) | (43.1 M) | (41.4 M) | (41.2 M) | (60 M) | (54 M) | (56.7 M) |
| MASS | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (13.4 M) | (12.8 M) | (22.2 M) | (31.7 M) | (36.4 M) | (72.2 M) | (65 M) | (61.7 M) |
| BWAY | (5.9 M) | (5.9 M) | (5.9 M) | (7.1 M) | (6.5 M) | (4.1 M) | (2.4 M) | (7.1 M) | (6.5 M) | (10.3 M) | (5.4 M) | (6.5 M) | (13.3 M) | (4.2 M) | 2.9 M | 3.4 M | 3.5 M |
| SENS | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.9 M) | (29.9 M) | (43.9 M) | (59.1 M) | (94 M) | (115.5 M) | (175.2 M) | (302.5 M) | 142.1 M | (60.4 M) | (78.6 M) | (70.8 M) | (74.3 M) |
| SGHT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (25.9 M) | (34.7 M) | (63 M) | (86.2 M) | (55.5 M) | (51.5 M) | (46.4 M) | (48.7 M) |
| DCTH | (2 M) | (30.9 M) | (51.9 M) | (30.3 M) | (17.4 M) | (14.7 M) | (18 M) | (45.1 M) | (19.2 M) | (8.9 M) | (24.2 M) | (25.6 M) | (36.5 M) | (47.7 M) | (26.4 M) | (23.7 M) | (24.9 M) |
| GNLX | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (14.9 M) | (17.8 M) | (5.2 M) | (28.3 M) | (29.9 M) | (26.9 M) | (28.2 M) |
| ALDX | (2.4 M) | (2.4 M) | (23.1 M) | 13.1 M | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (57.8 M) | (62 M) | (37.5 M) | (55.9 M) | (50.3 M) | (47.8 M) |
Neuropace and related stocks such as Cerus, Rxsight, and CVRx Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Neuropace financial statement analysis. It represents the amount of money remaining after all of Neuropace operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Neuropace | NPCE |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 455 North Bernardo |
| Exchange | NASDAQ Exchange |
USD 15.67
Check out Neuropace Performance and Neuropace Correlation. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Neuropace technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.